Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nogapendekin alfa inbakicept - Altor BioScience Corporation

Next Previous
Drug Profile

Nogapendekin alfa inbakicept - Altor BioScience Corporation

Alternative Names: ALT 803; ANKTIVA; IL-15N72D/IL-15Ra-Fc - Altor BioScience Corporation; IL-15N72D:IL-15RαSu/Fc fusion protein complex; IL-15sa - Altor BioScience Corporation; Interleukin 15 superagonist - Altor BioScience Corporation; N-803; Nogapendekin alfa inbakicept - ImmunityBio; Nogapendekin alfa inbakicept-pmln - Altor BioScience Corporation; Superagonist Interleukin-15:Interleukin-15 receptor alphaSu/Fc Fusion complex - Altor BioScience Corporation; VesAnktiva™

Latest Information Update: 10 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altor BioScience Corporation
  • Developer Altor BioScience Corporation; ImmunityBio; National Cancer Institute (USA)
  • Class Antineoplastics; Antiretrovirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 15 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bladder cancer
  • Phase III Non-small cell lung cancer
  • Phase II Acute myeloid leukaemia; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Glioblastoma; Hereditary nonpolyposis colorectal cancer; HIV infections; Liver cancer; Malignant melanoma; Merkel cell carcinoma; Myelodysplastic syndromes; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Phase I/II Endometrial cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Prostate cancer; Triple negative breast cancer
  • Phase I Cancer
  • No development reported COVID 2019 infections; HIV-1 infections

Most Recent Events

  • 02 Jun 2025 The US FDA grants expanded access authorization for Nogapendekin alfa inbakicept for the treatment of lymphopenia
  • 07 May 2025 ImmunityBio initiates an expanded access trial in Lymphopenia in USA (SC, Injection) (NCT06956547)
  • 05 May 2025 ImmunityBio requests an urgent meeting to resolve the inconsistencies between the directives provided at the January Meeting and receipt of the RTF letter for nogapendekin alfa inbakicept

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top